This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Nicole Van Der Weerden
Chief Executive Officer at Hexima Ltd


Doctor Nicole van der Weerden is Chief Executive Officer and Managing Director at Hexima Limited. She completed her PhD in Biochemistry at La Trobe University and her MBA at Melbourne Business School. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. Since completing her PhD, Nicole has worked for Hexima Limited and has led the discovery and development program for novel peptide therapeutics for fungal infections. Hexima’s lead product, HXP124, has recently completed phase I/IIa clinical trials in Australia with very promising results.

Agenda Sessions

  • The Commercial Development of a Peptide for Human Fungal Toenail Infections (Onychomycosis)